Teva Should Post Bond For Copaxone During Supreme Court Patent Review – Sandoz, Mylan Argue
This article was originally published in The Pink Sheet Daily
Executive Summary
Allowing an injunction against a Federal Circuit opinion would in essence decide the case in Teva’s favor, generic firms contend, since now-invalidated manufacturing patent is set to expire in September 2015 anyway.